Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

June 18, 2019: 6:30 – 8:30 p.m.

- **Executive Session** 6:00 - 6:30
- **Introductions and Approval of DUR Board Minutes** 6:30 - 6:35
  (Public Comment Prior to Board Action)
- **DVHA Pharmacy Administration Updates** 6:35 - 6:40
- **Medical Director Update** 6:40 - 6:45
- **Follow-up Items from Previous Meetings** 6:45 - 6:50
  - RetroDUR additional data: Use of Opioids for Chronic Pain
- **RetroDUR/ProDUR** 6:50 - 7:15
  - Introduce: Appropriate Use of Asthma Controller Medications
  - Data presentation: Adherence to Anti-retroviral Therapy for HIV
- **Clinical Update: Drug Reviews** 7:15-7:45
  (Public comment prior to Board action)

**Biosimilar Drug Reviews**
- None at this time

**Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)
- Krintafel® (tafenquine)
- Onpattro® (patisiran)
- Sympazan® (clobazam)
- Tegsedi® (inotersen)
- Tolsura® (itraconazole capsules)
- Ultomiris® (ravulizumab-cwvz)
- Yupelri® (revefenacin)

- **New Managed Therapeutic Drug Classes** 7:45 -7:45
  (Public comment prior to Board action)
  - None at this time

- **Therapeutic Drug Classes – Periodic Review** 7:45 - 8:30
  (Public comment prior to Board action)
- Antifungals, Oral
- Antifungals, Topical
- Bone Resorption Suppression and Related Agents
- Hypoglycemics, Incretin Mimetics/Enhancers & SGLT-2 Inhibitors
- Hypoglycemics, Insulin and Related Agents
- Hypoglycemics, Meglitinides
- Hypoglycemics, TZD Agents
- Immunologic Therapies for Asthma
- Multiple Sclerosis Agents

- **Review of Newly-Developed/Revised Criteria** 8:30 - 8:30
  (Public comment prior to Board action)
  - None at this time

- **General Announcements** 8:30 – 8:30
  **Selected FDA Safety Alerts**
  - None at this time

- **Adjourn** 8:30